KORU Medical Systems Presents Data Demonstrating Nursing Preference For Use Of KORU FreedomEdge Infusion System Over Manual Syringe Administration For Subcutaneous Oncology Infusion At Partnership Opportunities In Drug Delivery Conference
KORU Medical Systems Presents Data Demonstrating Nursing Preference For Use Of KORU FreedomEdge Infusion System Over Manual Syringe Administration For Subcutaneous Oncology Infusion At Partnership Opportunities In Drug Delivery Conference
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large-volume subcutaneous infusion solutions, this week presented data demonstrating nursing preference for the use of the KORU FreedomEdge Infusion System to administer subcutaneous oncology infusions in the clinic setting. The results of the case study were presented at the PODD 2024 Conference on October 28, 2024, in Boston, Massachusetts.
koru medical systems是一家领先的医疗科技公司，专注于开发、制造和商业化创新且以患者为中心的大容量皮下输液解决方案。本周，在波士顿马萨诸塞州举办的2024年PODD会议上，该公司介绍了数据，证明护理人员更倾向于在诊所环境中使用KORU FreedomEdge输液系统进行皮下肿瘤治疗的输液。该案例研究结果表明，诊所中护理人员更偏向于使用KORU FreedomEdge输液系统来进行皮下肿瘤治疗的输液。
The objective of the Nursing Preference Study was to assess time spent with patients, impact on nursing and patient comfort, and overall nurse preference when comparing manual syringe administration versus mechanical pump administration with the KORU FreedomEdge Infusion System during subcutaneous oncology biologic drug infusions. The study was conducted by KORU Medical across 6 hospitals in Denmark with 33 nurses administering more than 3,000 infusions of a >10mL oncology drug with an average administration time of approximately 10 minutes.
护理优先研究的目标是评估与患者交流的时间，对护理人员和患者舒适度的影响，以及在比较手动注射器与KORU FreedomEdge输液系统进行皮下肿瘤生物药物输液时的整体护理人员偏好。该研究由KORU Medical在丹麦的6家医院开展，33名护士共进行了3000多次大于10毫升的肿瘤药物输液，平均输注时间约为10分钟。
- Increased Patient Interaction: 97% of nurses reported having more time to interact with patients while using the KORU FreedomEdge Infusion System versus manual syringe administration
- Reduced Nurse Discomfort: 81% of nurses experienced less hand pain while using the KORU FreedomEdge Infusion System compared to manual syringe administration
- Ease of Use: 91% of nurses found the KORU FreedomEdge Infusion System easier to use, with a shorter setup time compared to manual syringe administration
- Reduced Patient Discomfort: 73% of nurses observed less patient pain during infusions with the KORU FreedomEdge Infusion System versus manual syringe administration
- Recommended by Nurses: 97% of nurses would recommend the KORU FreedomEdge Infusion System over manual syringeadministration, citing ease of use and reduced discomfort as key reasons
- 患者互动增加：97%的护士报告在使用KORU FreedomEdge输液系统时有更多时间与患者交流，而不是手动注射器。
- 减少护士不适：81%的护士在使用KORU FreedomEdge输液系统时经历较少的手部疼痛，而与手动注射器相比。
- 易于使用：91%的护士发现KORU FreedomEdge输液系统更易于使用，设置时间较手动注射器更短。
- 减少患者不适：73%的护士观察到在使用KORU FreedomEdge输液系统与手动注射器相比，输液过程中患者的疼痛减少。
- 护士推荐：97%的护士表示他们会推荐KORU FreedomEdge输液系统而不是手动注射器，原因是易于使用和减少不适。
Subcutaneous formulation of formerly intravenous biologics is a growing trend with oncology pharmaceutical manufacturers. There are five greater-than-5mL biologic oncology drugs that have been cleared for in-clinic administration by healthcare professionals for an estimated one million global infusions.1,2 Evidence indicates that subcutaneous administration of oncology therapy simplifies treatment protocol, reduces pressure on hospitals, and improves patients' quality of life.3 As further development of subcutaneous drug therapies increases, the optimization of drug administration has created a significant opportunity for drug delivery solutions like the KORU FreedomEdge Infusion System.
曾经为静脉注射的生物制药制品转为皮下注射是肿瘤制药制造商的一个增长趋势。全球有5种大于5毫升的生物制药肿瘤药物已获医疗专业人员批准在诊所进行约一百万次输液。证据表明，肿瘤治疗的皮下注射简化了治疗方案，减轻了医院的压力，并提高了患者的生活质量。随着皮下药物疗法的进一步发展，药物管理的优化为KORU FreedomEdge输液系统等药物输送解决方案创造了重要机遇。
